19.12
+2.91%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Novogene Co
Its shares trade on Shanghai under the ticker 688315.SS. It has been listed since 13 April 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.21bn and net income of CN¥166.1m. At that date it held total assets of CN¥3.94bn and shareholders' equity of CN¥2.65bn.
Novogene Co., Ltd. engages in the provision of genomic services and solutions. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-04-13. The firm mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The firm's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The firm conducts its businesses in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 13 Apr 2021
- Employees
- 2,284
- Website
- en.novogene.com ↗
Leadership
Pay as last reported
- Mr. Ruiqiang LiChairman of the Board, General ManagerCN¥428,300
- Mr. Jiashan ShiChief Financial OfficerCN¥830,200
- Mr. Qifeng WangDeputy General Manager, Secretary of the Board, DirectorCN¥1.0m
- Ms. Yanping LiDeputy General Manager
- Mr. Dawei WangDeputy General ManagerCN¥714,700
- Mr. Yang YuDeputy General Manager
- Mr. Xiao LiDirector
- Ms. Tianfan WangIndependent Director
- Ms. Ran ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Novogene's high-throughput sequencing technology supports genomic services in China and overseas markets.
- The company's DA8600 sequencers and gene mutation detection kits are key products for medical applications.
- 2,284 employees provide expertise in genomic services and bioinformatics analysis.
Weaknesses
- Novogene's reliance on high-throughput sequencing technology may limit diversification.
- The company's services are primarily focused on genomic applications without broader market expansion.
- Limited information on international market penetration beyond domestic operations.
Opportunities
- Growing demand for genomic services in medical and clinical research globally.
- Expansion of multi-omics research technology applications in life sciences.
- Increasing use of gene mutation detection kits in healthcare diagnostics.
Threats
- Competition from other genomic service providers in the Health Care sector.
- Regulatory changes affecting genomic data usage in medical applications.
- Economic downturns impacting healthcare spending on genomic research.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.